Stay updated on Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial
Sign up to get notified when there's something new on the Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial page.

Latest updates to the Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial page
- ChecktodayChange DetectedThe page revision was updated from v3.5.3 to v3.5.4, indicating a minor update to the page’s text or formatting rather than substantive changes to the study details.SummaryDifference0.0%

- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check22 days agoChange DetectedThe page’s UI/backend revision label was updated from version v3.5.2 to v3.5.3.SummaryDifference0.0%

- Check29 days agoChange DetectedAdded Revision: v3.5.2; Deleted Revision: v3.5.0.SummaryDifference0.0%

- Check43 days agoChange DetectedAdded a new MeSH term 'Primary interstitial lung disease specific to childhood' and a Genetic and Rare Diseases Information Center resources link to the study page.SummaryDifference0.1%

- Check58 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check65 days agoChange DetectedRevision: v3.4.3 replaces the previous v3.4.2 on the page.SummaryDifference0.0%

Stay in the know with updates to Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial page.